Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | MHRA join the speaker line-up at 6th annual RNA Therapeutics SummitBy: SMi Group Other event highlights: 1. AstraZeneca share clinical data on modulating intractable oncology targets: Next generation ASO technology is poised to become a key therapeutic modality to modulate intractable oncology targets. Chief Scientist, David Blakey will be presenting clinical data in his keynote address entitled: Tackling Intractable targets in oncology. 2. Roche unlock the potential with locked nucleic acids: Roche recently announced the launch of the SeqCap RNA Target Enrichment System for RNA-Seq applications. The system was designed to enable researchers to achieve significantly enhanced discovery power and targeting efficiency of RNA-Seq. Hear more as Vice President of Drug Discovery & Alliance, Bo Rode Hansen, explains the most recent thinking on increasing productivity of RNA therapeutics development. 3. GSK answer the question: How do we deliver macromolecules to the right address?GSK Director, Steven Hood will answer this and more in a presentation that discusses pharmacological evaluation in vitro and in vivo, bioconjugates, nanoassemblies and cell/tissue imaging. 4. Industry KOL Dirk Haussecker provides an opening keynote on Day 2: "My perspective is somewhat unique as I can draw on both my scientific and financial experiences in this area and maintain an active dialogue with the drug developers, basic scientists, and investors in this field. Conference delegates should come away with a better understanding on the macrostructural dynamics in the industry." 5. Sarepta Therapeutics present findings from a 120 week trial: Distinguished Scientist, Ryszard Kole will be presenting the results from a continuing trial after 120 weeks of treatment. The keynote address entitled: From RNA splicing to Eterplirsen trials - a drug for Duchenne muscular dystrophy, will provide insight into Eteplirsen induced exon skipping of 51 in dystrophin pre-mRNA in DMD patients and showcase the invention of RNA splicing modulation This is just a snapshot of what will be covered. Other key speakers will include Silence Therapeutics, CRISPR Therapeutics, Leiden University Medical Centre, UCL and University of Oxford. For further details visit the website at: http://www.smi- RNA Therapeutics 2015 16 - 17 Feb 2015 Marriott Regents Park Hotel, London, UK http://www.smi- Sponsored by Lipocalyx and Silence Therapeutics --- END --- About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to- End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|